Global Fund announces new agreements with malaria treatment suppliers

The Global Fund announced on Tuesday new framework agreements with artemisinin-based combination therapy (ACT) suppliers to improve the delivery of anti-malarial medicines.

The predicted savings of the agreements over a two-year period is projected to be approximately $100 million.

"A smarter approach to procurement of high-volume medicines means more lives can be saved," Mark Dybul, the executive director of the Global Fund, said. "This is a great case of creating value for money, and increasing impact."

Under the agreement, nine ACT suppliers will enter into contracts to deliver allocated and committed volumes of drugs over two years. The agreements are intended to be financially beneficial while improving pipeline visibility, delivery performance and market sustainability, as well as increase local production of the treatments.

The United Kingdom's Department of International Development and other partners developed the private sector co-payment ATC mechanism. Other organizations that have aligned their efforts to support the new framework include the World Health Organization, the United Nations Children's Fund and the Clinton Health Access Initiative.

ACTs have become a mainstay of malarial treatment, and helped to contribute to a 49 percent drop in mortality rates from the disease in Africa since 2000.

Malaria affects approximately 200 million people every year, with 80 percent of cases in sub-Saharan Africa.